MX2020002381A - Implantes intraoculares que contienen prostamida y metodos para su uso. - Google Patents

Implantes intraoculares que contienen prostamida y metodos para su uso.

Info

Publication number
MX2020002381A
MX2020002381A MX2020002381A MX2020002381A MX2020002381A MX 2020002381 A MX2020002381 A MX 2020002381A MX 2020002381 A MX2020002381 A MX 2020002381A MX 2020002381 A MX2020002381 A MX 2020002381A MX 2020002381 A MX2020002381 A MX 2020002381A
Authority
MX
Mexico
Prior art keywords
prostamide
implants
methods
eye
intraocular implants
Prior art date
Application number
MX2020002381A
Other languages
English (en)
Inventor
Michael R Robinson
Alazar N Ghebremeskel
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2020002381A publication Critical patent/MX2020002381A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

Implantes intraoculares que contienen prostamida que se biodegradan en el ojo y que son eficaces para reducir la presión intraocular en un ojo durante un período sostenido. Los implantes contienen generalmente una prostamida, tal como bimatoprost, y al menos tres polímeros biodegradables distintos que se seleccionan de polímeros de poliláctido y poli(láctido-co-glicólido) y se optimizan para su colocación y compatibilidad con la cámara anterior del ojo, particularmente el ángulo de la cámara anterior. Se describen métodos para confeccionar y utilizar los implantes para reducir la hipertensión ocular y la presión intraocular en un paciente.
MX2020002381A 2013-10-31 2016-04-27 Implantes intraoculares que contienen prostamida y metodos para su uso. MX2020002381A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361898241P 2013-10-31 2013-10-31

Publications (1)

Publication Number Publication Date
MX2020002381A true MX2020002381A (es) 2020-07-22

Family

ID=51982758

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005508A MX2016005508A (es) 2013-10-31 2014-10-31 Implantes intraoculares que contienen prostamida y metodos para su uso.
MX2020002381A MX2020002381A (es) 2013-10-31 2016-04-27 Implantes intraoculares que contienen prostamida y metodos para su uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016005508A MX2016005508A (es) 2013-10-31 2014-10-31 Implantes intraoculares que contienen prostamida y metodos para su uso.

Country Status (29)

Country Link
US (6) US9492316B2 (es)
EP (5) EP3669865A1 (es)
JP (2) JP6482547B2 (es)
KR (1) KR102307281B1 (es)
CN (2) CN105682645B (es)
AU (3) AU2014342017B2 (es)
BR (1) BR112016009575B1 (es)
CA (1) CA2926515C (es)
CL (1) CL2016001041A1 (es)
CY (2) CY1119961T1 (es)
DK (2) DK3351239T3 (es)
ES (2) ES2661666T3 (es)
HK (1) HK1258014A1 (es)
HU (2) HUE050902T2 (es)
IL (2) IL244859B (es)
MX (2) MX2016005508A (es)
MY (1) MY177958A (es)
NO (1) NO3102476T3 (es)
PH (1) PH12016500767B1 (es)
PL (2) PL3062775T3 (es)
PT (2) PT3062775T (es)
RU (1) RU2650614C2 (es)
SA (1) SA516371022B1 (es)
SG (2) SG11201603383VA (es)
SI (2) SI3062775T1 (es)
TR (1) TR201802759T4 (es)
UA (1) UA119853C2 (es)
WO (1) WO2015066548A1 (es)
ZA (1) ZA201602556B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP3669865A1 (en) * 2013-10-31 2020-06-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
MX2016007345A (es) * 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
WO2015184173A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
BR112017019025A2 (pt) 2015-03-06 2018-07-31 Envisia Therapeutics Inc aplicadores de implante e métodos para administrar implantes.
CA2993340C (en) 2015-07-23 2024-04-30 Aerie Pharmaceuticals, Inc. Intravitreal drug delivery systems for the treatment of ocular conditions
US20210228408A1 (en) * 2015-07-23 2021-07-29 Allergan, Inc. Glaucoma Treatment Via Intracameral Ocular Implants
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
EP3352749A4 (en) 2015-09-22 2019-09-04 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CN109937025B (zh) 2016-04-20 2022-07-29 多斯医学公司 生物可吸收眼部药物的递送装置
US11497399B2 (en) 2016-05-31 2022-11-15 Qura, Inc. Implantable intraocular pressure sensors and methods of use
US20190374380A1 (en) * 2016-09-02 2019-12-12 Envisia Therapeutics, Inc. Implant applicators
US20190192341A1 (en) * 2017-11-09 2019-06-27 Allergan, Inc. Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
US20200069577A1 (en) * 2018-08-30 2020-03-05 Yunxiang Liu Ophthalmic formulations, process for preparing the same and method for administering the same
AU2019400857A1 (en) * 2018-12-21 2021-08-12 Re-Vana Therapeutics Ltd Coated ocular implants
BR112021026265A2 (pt) 2019-06-27 2022-06-14 Layerbio Inc Métodos e sistemas de entrega de dispositivos oculares
AU2021215929A1 (en) 2020-02-06 2022-08-04 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases
CA3184833A1 (en) 2020-07-10 2022-01-13 Michael Robinson Posterior chamber delivery device for sustained release implant
IL299577A (en) * 2020-07-21 2023-03-01 Allergan Inc Intraocular implant with high prostamide loading
WO2022232588A1 (en) 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749776A (en) 1970-08-28 1973-07-31 Allergan Pharma Method for blocking prostaglandin activity
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
CA1311686C (en) 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
MY113268A (en) 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5545665A (en) 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
US6395787B1 (en) 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US20040175410A1 (en) 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
HUP0303197A3 (en) 2000-07-14 2008-03-28 Allergan Inc Compositions containing alpha-2 adrenergic agonist components
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
EP1387671A1 (en) 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Implantable drug delivery device and use thereof
US20030220376A1 (en) 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20050245509A1 (en) 2002-08-29 2005-11-03 Santen Pharmacecutical Co., Ltd. Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
AU2003295409B2 (en) 2002-11-06 2010-02-11 Durect Corporation Controlled release depot formulations
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20070212395A1 (en) 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20230026451A1 (en) * 2004-04-30 2023-01-26 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) * 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050282902A1 (en) 2004-06-22 2005-12-22 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US7101904B2 (en) 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7473738B2 (en) * 2004-09-30 2009-01-06 Johnson & Johnson Vision Care, Inc. Lactam polymer derivatives
AU2005294382A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
CN101437478A (zh) * 2004-10-04 2009-05-20 Qlt美国有限公司 聚合送递制剂的眼部送递
US7101906B2 (en) 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
EP1846354B1 (en) 2005-01-14 2010-04-28 Allergan, Inc. Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
PL1856042T3 (pl) 2005-03-10 2012-11-30 Allergan Inc Podstawione gamma laktamy jako środki terapeutyczne
CA2602535A1 (en) 2005-05-06 2006-11-16 Allergan, Inc. Substituted beta-lactams and their use in medicine
US8039507B2 (en) 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
DE102005033101A1 (de) 2005-07-15 2007-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Resorbierbare Polyetherester und ihre Verwendung zur Herstellung von medizinischen Implantaten
AU2006295305B2 (en) 2005-09-16 2013-01-31 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US20090082321A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
WO2007056087A1 (en) 2005-11-03 2007-05-18 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
AU2007226957B2 (en) 2006-03-20 2013-08-15 Allergan, Inc. Substituted gamma lactams as prostaglandin EP2 agonists
US7439372B2 (en) 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
US7491844B2 (en) 2006-05-04 2009-02-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US20070293873A1 (en) 2006-06-19 2007-12-20 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US20070298073A1 (en) 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9039761B2 (en) * 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20090081277A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
US7740604B2 (en) 2007-09-24 2010-06-22 Ivantis, Inc. Ocular implants for placement in schlemm's canal
EP2296621A1 (en) 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20100098772A1 (en) 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
CN102341144B (zh) * 2009-01-23 2014-10-29 Qlt股份有限公司 一种或多种药剂的持续释放递送
US20100247606A1 (en) 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP2512389B1 (en) 2009-12-16 2015-09-02 Allergan, Inc. Intracameral devices for sustained delivery
KR20180117211A (ko) 2010-01-22 2018-10-26 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
US20130071349A1 (en) * 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
CN103619837A (zh) 2011-04-22 2014-03-05 阿勒根公司 用于治疗疼痛的脂肪酸酰胺水解酶抑制剂
EP3967297A1 (en) 2011-04-29 2022-03-16 Allergan, Inc. Sustained release latanoprost implant
EP3669865A1 (en) * 2013-10-31 2020-06-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
US20190192341A1 (en) * 2017-11-09 2019-06-27 Allergan, Inc. Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect
IL299577A (en) * 2020-07-21 2023-03-01 Allergan Inc Intraocular implant with high prostamide loading

Also Published As

Publication number Publication date
SI3351239T1 (sl) 2020-09-30
PT3351239T (pt) 2020-07-03
PL3351239T3 (pl) 2020-12-28
IL268976A (en) 2019-10-31
HUE036554T2 (hu) 2018-07-30
CA2926515A1 (en) 2015-05-07
PT3062775T (pt) 2018-03-06
US9980974B2 (en) 2018-05-29
ES2661666T3 (es) 2018-04-03
CY1119961T1 (el) 2018-12-12
PH12016500767A1 (en) 2016-06-20
MY177958A (en) 2020-09-28
US20180271878A1 (en) 2018-09-27
SG10201800978UA (en) 2018-03-28
CN105682645A (zh) 2016-06-15
JP6482547B2 (ja) 2019-03-13
CN105682645B (zh) 2019-09-06
AU2020201778B2 (en) 2021-11-04
CL2016001041A1 (es) 2016-10-28
AU2014342017A1 (en) 2016-06-02
AU2022200742B2 (en) 2024-08-22
JP2019088881A (ja) 2019-06-13
CN110302138B (zh) 2022-09-30
EP4406535A2 (en) 2024-07-31
HUE050902T2 (hu) 2021-01-28
US20240108635A1 (en) 2024-04-04
US9492316B2 (en) 2016-11-15
IL268976B (en) 2021-04-29
EP3062775A1 (en) 2016-09-07
BR112016009575A2 (pt) 2017-08-01
BR112016009575B1 (pt) 2022-12-13
EP3351239A1 (en) 2018-07-25
DK3062775T3 (en) 2018-03-12
CY1123077T1 (el) 2021-10-29
SI3062775T1 (en) 2018-05-31
CN110302138A (zh) 2019-10-08
IL244859A0 (en) 2016-05-31
AU2014342017B2 (en) 2020-01-23
MX2016005508A (es) 2016-08-03
WO2015066548A1 (en) 2015-05-07
NZ718992A (en) 2021-11-26
TR201802759T4 (tr) 2018-03-21
IL244859B (en) 2019-08-29
DK3351239T3 (da) 2020-06-29
US20150118279A1 (en) 2015-04-30
SA516371022B1 (ar) 2018-03-04
EP3062775B1 (en) 2017-12-06
CA2926515C (en) 2020-11-24
NO3102476T3 (es) 2018-05-26
ZA201602556B (en) 2017-06-28
HK1258014A1 (zh) 2019-11-01
EP4046628A1 (en) 2022-08-24
PH12016500767B1 (en) 2016-06-20
JP6814829B2 (ja) 2021-01-20
EP3669865A1 (en) 2020-06-24
US20220218721A1 (en) 2022-07-14
US20210030766A1 (en) 2021-02-04
US20170056412A1 (en) 2017-03-02
JP2017500282A (ja) 2017-01-05
RU2650614C2 (ru) 2018-04-16
RU2016116378A (ru) 2017-12-01
KR20160077121A (ko) 2016-07-01
EP3351239B1 (en) 2020-04-01
AU2022200742A1 (en) 2022-02-24
UA119853C2 (uk) 2019-08-27
KR102307281B1 (ko) 2021-09-29
ES2805880T3 (es) 2021-02-15
SG11201603383VA (en) 2016-05-30
PL3062775T3 (pl) 2018-05-30
AU2020201778A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
MX2020002381A (es) Implantes intraoculares que contienen prostamida y metodos para su uso.
WO2014143754A3 (en) Prostamide-containing intraocular implant
WO2011091205A3 (en) Intracameral sustained release therapeutic agent implants
CY1121064T1 (el) Μειωση ενδοφθαλμιας πιεσης με ενδοθαλαμικα εμφυτευματα βιματοπροστης
EP2838584A4 (en) EYE IMPLANTS FOR DELIVERY INTO A FRONT EYE CHAMBER
BR112017022623A2 (pt) implantes de córnea
WO2010062523A3 (en) Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
PH12015501032A1 (en) Curvature changing accommodative intraocular lens
EP3730104A4 (en) IMPLANT DEVICE FOR EYE DISEASE, INTENDED TO REGULATE INTRAOCULAR PRESSURE
EA201590968A1 (ru) Устройства расширяющихся офтальмологических имплантатов и способы
MY197845A (en) Pharmaceutical composition
MY171920A (en) Prevention and treatment of ocular conditions
EP3494959A3 (en) Sustained release latanoprost implant
IN2014CN03269A (es)
MX2016004378A (es) Sistema de diagnostico y metodo de diagnostico.
MX2016001300A (es) Estructura de lente intraocular.
WO2018213842A3 (en) Elestomeric fibrous hybrid scaffold for in vitro and in vivo formation
RU2016136333A (ru) Фармакологическая офтальмологическая композиция, используемая в коррекции пресбиопии, и ее введение
MX2022002306A (es) Metodos de tratamiento de enfermedades oculares con un implante para la administracion sostenida de farmacos.
GB2525994A (en) Antimicrobial ophthalmic contact lenses
BR112014020424A2 (pt) ponta de fragmentação, dispositio de cirurgia intra-ocular fornecido com as mesmas, método para suprimir ocorrência de cavitação e método de cirurgia de catarata
BR112017007095A2 (pt) conjugados e derivados de prostaglandina para tratamento de glaucoma e hipertensão ocular
IN2014DN09713A (es)
UY33562A (es) Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma
EP3329859A4 (en) IRISDILATION RING FOR CATARACT SURGERY WITHOUT INJECTOR